SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2019 07:00

RNS Number : 1051H
James Halstead PLC
30 July 2019
 

 

 

 

30 July 2019

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2019.

 

We are pleased to report that sales for the year were ahead of the comparative year and at a record level. This, we feel, represents a creditable performance in still difficult trading conditions. Flooring installations through the year were wide ranging such as Harrow School, Euro Disney's Hotel New York and Chanel concessions across the globe and the Al Thumama Stadium in Qatar. Our healthcare business continues to make good progress and projects completed included Poissy Hospital in France and the newly built Quillota Hospital in Chile. It is particularly pleasing to report that our UK turnover (representing about 35% of total sales) is ahead of the prior year, by some 7%, in a market that seems to be quite robust despite the well reported high street retailer issues.

 

Across many regions, but especially in Europe competition is ever increasing with new entrants peddling an increasing array of flooring of various degrees of quality and availability. In the German market we have maintained market share but turnover was at a lower level. There are markets with double digit growth and France, South America and Holland are examples. We remain confident that our investment in marketing, sampling, sales representation and training / technical support continue to differentiate us from the pack.

 

Raw material prices are stable and the availability problems of last year have ameliorated and working capital remains robustly managed with our cash generation secure. Our long term focus on delivery of shareholder returns is undiminished.

 

Our profit for the year has grown and will be at a record level, representing modest growth.

 

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

Nick Moore

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

Ben Thorne

Dominic Morley

Arden Partners (Broker)

Telephone: 020 7614 5900

Tom Price

Matthew Groves

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDKLFLKDFFBBE
Date   Source Headline
16th Mar 20153:46 pmRNSNotice of Interim Results
3rd Mar 20153:00 pmRNSTotal Voting Rights
30th Jan 20157:00 amRNSPre Close Trading Statement
6th Jan 20154:11 pmRNSBlocklisting Interim Review
6th Jan 201511:21 amRNSTotal Voting Rights
5th Dec 20147:00 amRNSAGM Statement
3rd Nov 20147:00 amRNSTotal Voting Rights
24th Oct 20143:24 pmRNSAnnual Financial Report
1st Oct 20149:25 amRNSTotal Voting Rights
1st Oct 20147:00 amRNSPreliminary Results
27th Aug 20147:00 amRNSNotice of Preliminary Results
31st Jul 20147:00 amRNSPre-Close Trading Statement
21st Jul 20143:50 pmRNSDirectors' Shareholdings
17th Jul 20144:51 pmRNSDirectors exercise of share options
1st Jul 20147:00 amRNSBlocklisting Interim Review
1st Jul 20147:00 amRNSTotal Voting Rights
3rd Jun 20147:00 amRNSTotal Voting Rights
1st May 201411:10 amRNSTotal Voting Rights
31st Mar 20147:00 amRNSInterim Results
3rd Feb 20147:00 amRNSPre Close Trading Statement
20th Jan 20149:40 amRNSPurchase of own shares and directors' dealings
6th Jan 20144:30 pmRNSBlocklisting Interim Review
6th Dec 20137:00 amRNSAGM Statement
4th Nov 201311:00 amRNSTotal Voting Rights
28th Oct 20135:25 pmRNSAnnual Financial Report
28th Oct 20134:18 pmRNSDirectors exercise of share options
4th Oct 201312:40 pmRNSTotal Voting Rights
1st Oct 20137:00 amRNSPreliminary Announcement of Audited Results
23rd Sep 201312:55 pmRNSNotice of Preliminary Results
31st Jul 20137:00 amRNSPre-close Trading Statement
16th Jul 201312:00 pmRNSBlocklisting Interim Review
21st Jun 20134:35 pmRNSPrice Monitoring Extension
2nd May 201311:10 amRNSTotal Voting Rights
28th Mar 20137:00 amRNSInterim Results
1st Feb 201311:15 amRNSNotice of Interim Results Date Change
31st Jan 20134:00 pmRNSTotal Voting Rights
31st Jan 20137:00 amRNSPre-close Trading Statement
10th Jan 201311:00 amRNSIssue of Equity and Total Voting Rights
7th Jan 20139:00 amRNSBlocklisting Interim Review
11th Dec 20127:00 amRNSBonus Issue
7th Dec 20124:40 pmRNSSecond Price Monitoring Extn
7th Dec 20124:35 pmRNSPrice Monitoring Extension
7th Dec 20127:00 amRNSAGM Statement
3rd Dec 20127:00 amRNSTotal Voting Rights
1st Nov 20127:00 amRNSTotal Voting Rights
23rd Oct 20127:00 amRNSAnnual Financial Report
1st Oct 20127:00 amRNSPreliminary Audited Results
3rd Sep 20127:00 amRNSTotal Voting Rights
30th Jul 20127:00 amRNSPre-close Trading Statement
2nd Jul 20129:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.